CliffBio
small molecule

LODINE XL

ETODOLAC

Loss of exclusivity—loss of exclusivity
CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand nameLODINE XL
Active ingredientETODOLAC
Strength400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 1996
Marketing statusDISCN

More from Wyeth

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.